Mechanism of the combination effect of wild-type TP53 gene transfection and cisplatin treatment for ovarian cancer xenografts

M. Shimada, J. Kigawa, Y. Kanamori, H. Itamochi, M. Takahashi, S. Kamazawa, S. Sato, N. Terakawa

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

To clarify the effect of a combination treatment consisting of a recombinant adenovirus carrying a wild-type TP53 gene (AxCATP53) and cisplatin (CDDP), we examined p53-dependent apoptosis in ovarian cancer xenografts with and without the wild-type TP53 gene. Severe combined immunodeficiency (SCID) mice were implanted with ovarian cancer cell lines consisting of SK-OV-3 cells without the TP53 gene and KF cells with the TP53 gene. In SK-OV-3 and KF tumours, the inhibitory effect of the combination treatment on tumour growth was significant, compared with a single treatment with CDDP alone or AxCATP53 alone. The apoptotic index increased significantly after combination treatment in the SK-OV-3 tumours. The expression of Bax protein in SK-OV-3 tumours was weak, but strengthened after TP53 gene transfection. In contrast, AxCATP53 transfection did not affect CDDP-induced apoptosis in the KF tumours. Therefore, combination treatment of AxCATP53 and CDDP may be a new strategy for treating ovarian cancer with or without the TP53 gene. Copyright (C) 2000 Elsevier Science Ltd.

Original languageEnglish
Pages (from-to)1869-1875
Number of pages7
JournalEuropean Journal of Cancer
Volume36
Issue number14
DOIs
Publication statusPublished - 2000 Sep
Externally publishedYes

Keywords

  • CDDP
  • Ovarian cancer
  • Recombinant adenovirus
  • TP53 gene transfer
  • Xenograft

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Mechanism of the combination effect of wild-type TP53 gene transfection and cisplatin treatment for ovarian cancer xenografts'. Together they form a unique fingerprint.

Cite this